方法：选择Ⅲ～Ⅴ期糖尿病视网膜病变患者66例118眼随机分为治疗组33例62眼和对照组33例56眼，治疗组给予明睛合剂联合氩激光治疗，对照组仅给予氩激光光凝治疗，同时设立空白对照组30眼。采用双抗体夹心酶联免疫吸附试验ELISA法定量检测治疗组及对照组治疗前后血浆VEGF含量的变化，观察治疗前后最佳矫正视力、眼底及荧光素眼底血管造影的改变并同时行糖化血红蛋白(HbA1c)、凝血功能及肝肾功能的检测。

结果：治疗前DR患者血浆VEGF水平较空白对照组明显升高(P<0.05)，联合治疗3mo后治疗组血浆VEGF水平显著下降，同时血清HbA1c水平有所降低，与对照组相比差异有统计学意义(P<0.05)。联合治疗3mo后治疗组最佳矫正视力及荧光素眼底血管造影的改善程度较对照组显著好转。

结论：明睛合剂联合氩激光治疗DR，可以有效降低DR患者血浆VEGF水平，稳定血糖水平，改善视网膜功能，从而延缓DR病情的发展。

METHODS:The 66 patients(118 eyes)with DR at Ⅲ～Ⅴ stage were randomly divided into two groups(treatment group and control group). The control group(33 patients with 56 eyes)was treated with argon laser, and the treatment group(33 patients with 62 eyes)was treated with mingjing decoction combining with argon laser, and a blank group(30 eyes)was set up. The levels of plasma VEGF were detected by enzyme linked immunosorbent assay(ELISA). The results of best corrected visual acuity and fundus fluorescein angiography(FFA)were analyzed, as well as detected glycosylated hemoglobin(HbA1c), blood coagulation function and the function of liver and kidney.

RESULTS:Patients with DR had significantly risen plasma VEGF before treatment when compared with blank control group(P<0.05). After 3mo of combined treatment, the levels of plasma VEGF significantly reduced and HbA1c decreased in patients treated with mingjing decoction and argon laser, there were statistically significant difference compared to control group(P<0.05). In the treatment group, the best corrected visual acuity and FFA were significantly improved in patients treated with mingjing decoction combining with argon laser compared to patients treated with argon laser alone after 3mo of combined treatment.

CONCLUSION:Mingjing decoction combining with argon laser for DR can effectively reduce the level of plasma VEGF, stabilize blood sugar levels, improve the function of retina, and delay DR progresses.